Cetuximab (Erbitux)

References

1. 1.↵
   1. Blick SK,
   2. Scott LJ

   . Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 2007; 67: 2585–607

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Wong SF

   . Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 2005; 27: 684–94

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Steiner P,
   2. Joynes C,
   3. Bassi R,
   4. et al

   . Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin Cancer Res 2007; 13: 1540–51

   Abstract/FREE Full Text
4. 4.↵
   1. Martinelli E,
   2. De Palma R,
   3. Orditura M,
   4. et al

   . Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009; 158: 1–9

   PubMedWeb of Science
5. 5.↵
   Erbitux (Cetuximab); [package insert]. New York and Princeton, New Jersey: ImClone Systems and Bristol-Myers Squibb; 2009
6. 6.↵
   1. Ettinger DS

   . Emerging profile of cetuximab in non-small cell lung cancer. Lung Cancer 2009 Sep 25. [Epub ahead of print]
7. 7.↵
   1. Herbst RS

   . Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59 (2 suppl): 21–26

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Pérez-Soler R

   . HER1/EGFR targeting: refining the strategy. Oncologist 2004; 9: 58–67

   Abstract/FREE Full Text
9. 9.↵
   1. Fojo T,
   2. Grady C

   . How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009; 101: 1044–48. Epub 2009 Jun 29

   Abstract/FREE Full Text
10. 10.↵
    1. Koukourakis MI,
    2. Tsoutsou PG,
    3. Karpouzis A,
    4. et al

    . Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2009 Sep 8. [Epub ahead of print]
11. 11.↵
    1. Birnbaum A,
    2. Dipetrillo T,
    3. Rathore R,
    4. et al

    . Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. Am J Clin Oncol 2009 Sep 25. [Epub ahead of print]
12. 12.↵
    1. Brown B,
    2. Diamantopoulos A,
    3. Bernier J,
    4. et al

    . An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health 2008; 11: 791–99. Epub 2008 Jan 11

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Mittmann N,
    2. Au HJ,
    3. Tu D,
    4. et al

    . Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst 2009; 101: 1182–92. Epub 2009 Aug 7

    Abstract/FREE Full Text
14. 14.↵
    1. Holmer AF

    . Cetuximab in colon cancer. N Engl J Med 2004; 351: 1575–76

    CrossRefPubMed